Key terms
About OCUP
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OCUP news
Apr 11
10:05am ET
Ocuphire Pharma announces enrollment of first patient in LYNX-2 Phase 3 study
Apr 02
7:20am ET
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)
Apr 01
7:16am ET
Ocuphire Pharma announces U.S. commercial launch of RYZUMVI
Mar 27
4:44pm ET
Ocuphire Pharma Engages Investors with Presentation Update
Mar 20
7:51am ET
Ocuphire Pharma price target lowered to $20 from $24 at Alliance Global
Mar 11
7:10am ET
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Merus (MRUS) and Eli Lilly & Co (LLY)
Mar 11
6:28am ET
Buy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy Treatment
Mar 08
8:08am ET
Ocuphire Pharma expects cash to fund operations into mid-2025
Mar 08
8:08am ET
Ocuphire Pharma reports Q4 EPS (21c), consensus (5c)
Feb 16
4:12pm ET
Ocuphire Pharma Welcomes Nirav Jhaveri as New CFO
Feb 14
8:14am ET
Ocuphire Pharma appoints Jayagopal as CSDO, Jhaveri as CFO
Feb 05
8:08am ET
Ocuphire Pharma announces presentation on APX3330
No recent news articles are available for OCUP
No recent press releases are available for OCUP
OCUP Financials
Key terms
Ad Feedback
OCUP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OCUP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
